Blackstone Inc.NYSE: BX

Blackstone Life Sciences Announces $750 Million R&D Funding Agreement

· Issued by Blackstone Inc. via Business Wire

Summary by 6ix AI

Funds managed by Blackstone Life Sciences, a private investment platform focused on life sciences, will provide $750 million in development funding to Johnson & Johnson for the Phase 3 (late-stage) clinical development of OLN324. OLN324 is an investigational therapy for serious retinal vascular diseases, which affect blood vessels in the eye's retina.

Key details

  • The funding covers the Phase 3 clinical program of OLN324, including wet age-related macular degeneration (a blood-vessel form of age-related vision loss) and diabetic macular edema (swelling in the retina caused by diabetes).
  • Blackstone will finance the program following the expected closing of Johnson & Johnson's acquisition of Ollin Biosciences, Inc.
  • In return, Blackstone is entitled to certain regulatory and sales milestone payments and single digit royalties.

What’s still pending

  • The funding agreement is subject to Johnson & Johnson's acquisition of Ollin Biosciences, Inc.
  • The acquisition is subject to customary closing conditions, including receipt of regulatory approvals.

6ix AI wrote this summary from the release below and checked it against the release.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blackstone announced today that funds managed by Blackstone Life Sciences (“Blackstone”) will provide $750 million in development funding to Johnson & Johnson to support the Phase 3 clinical development of OLN324, an investigational therapy for serious retinal vascular diseases. Specifically, Blackstone will finance the Phase 3 clinical program of OLN324, including wet age-related macular degeneration and diabetic macular edema, following the expected closing of the acquisition of Ollin Biosciences, Inc. (“Ollin”).

“We are pleased to expand our relationship with Johnson & Johnson by supporting the Phase 3 development of OLN324,” said Dr. Nicholas Galakatos, Global Head of Blackstone Life Sciences. “Our financing demonstrates our ability to provide capital at scale to help leading pharmaceutical companies pursue strategic opportunities and advance innovative medicines that have the potential to improve patients’ lives.”

“OLN324 has demonstrated encouraging early clinical results and represents a differentiated approach to treating serious retinal vascular diseases that could deliver meaningful benefits for patients,” said Kiran Reddy, Senior Managing Director at Blackstone Life Sciences. “We are excited to work with Johnson & Johnson to help advance this promising new treatment option to patients.”

The agreement is subject to the acquisition of Ollin by Johnson & Johnson, which is subject to customary closing conditions including receipt of regulatory approvals. As part of its investment, Blackstone is entitled to certain regulatory and sales milestone payments as well as single digit royalties.

About Blackstone Life Sciences

Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within the key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients’ lives and currently has $18 billion in assets under management.

View original source (Business Wire)Blackstone Inc. on 6ix

Story so far

Earlier from Blackstone

Later from Blackstone

All Blackstone news releases